Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will compare salbutamol reversibility of methacholine induced bronchoconstriction between a pressurized metered dose inhaler with a spacer versus nebulizer administration using a vibrating mesh nebulizer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| salbutamol delivered via pressurized metered dose inhaler | Active Comparator | 200mcg of salbutamol will be delivered using a pressurized metered dose inhaler plus spacer |
|
| placebo | Placebo Comparator | normal saline will be administered with a vibrating mesh nebulizer and 200mcg of placebo will be administered using a pressurized metered dose inhaler plus spacer |
|
| salbutamol delivered with vibrating mesh nebulizer | Experimental | 200microliters of salbutamol will be administered using a vibrating mesh nebulizer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| salbutamol aqueous solution | Drug | administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lung function recovery | Maximal recovery in FEV1 and FVC (absolute volume and percent) | up to 60 minutes post salbutamol administration |
| Measure | Description | Time Frame |
|---|---|---|
| Time to lung function recovery | Area under the curve from start of salbutamol administration to time at which maximal recovery occurs | 0-60 minutes |
| Heart rate | change in pulse after salbutamol administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Don Cockcroft, MD | University of Saskatchewan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall | Saskatoon | Saskatchewan | S7N 0W8 | Canada |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| salbutamol pressurized metered dose inhaler | Drug | administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer |
|
| placebo | Other | matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer |
|
| 0-60 minutes |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |